Phase IV Trial,The Efficacy and Safety Study of Fuganlin Oral Liquid in Children With Acute Upper Respiratory Infection

• Status: Completed
• Trial end date: 2017-05-01
• Target enrollment: 0
• Participant gender: All

Summary

Phase IV trial,Single-arm, multi-centre clinical trial to assess the efficacy and safety of Fuganlin Oral Liquid in children with acute upper respiratory infection

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Guangzhou Yipinhong Pharmaceutical CO.,LTD

Criteria

Inclusion Criteria:

1. Patients diagnosed as acute upper respiratory infection.

2. Patients with acute upper respiratory infection diagnosed as Tradition Chinese Medicine syndrome qi deficiency wind-heat.

3. Patients aged 1 to 12 years old.

4. Parents or guardians agreed to participate this study and signed the informed consent.

Exclusion Criteria:

1. Patients whose total numbers of white blood cells around above1.3ULN.

2. Patients diagnosed as suppurative tonsillitis, otitis media, bronchitis and other airway.

3. Patients allergic to the test drug.

4. Serious cardiovascular, liver,kidney and other primary systemic diseases.

5. Patients should not be included in group according to investigator's evaluation.